# Thymogen IM862 in metastatic kidney cancer: phase II trial

Source: https://pepvault.app/research/thymogen-deplanque-2004

Last updated: 2026-11-18

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Research](https://pepvault.app/research) [Thymogen](https://pepvault.app/research#thymogen)

Clinical trial · people

# Thymogen (IM862): 8 of 25 kidney cancer patients had stable disease

Checked against the paper November 2026 Clinical trial [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The takeaway

In this trial, IM862 given alone was well tolerated but did not shrink spreading kidney cancer, and the team advised against testing it further this way in these patients.

- **Kind:** Clinical trial
- **Studied in:** People
- **Number studied:** 25
- **Published:** 2004
- **Journal:** Br J Cancer

## What they tested

The team tested whether IM862, the dipeptide also known as Thymogen, could shrink or control metastatic renal cell carcinoma (kidney cancer that has spread), and whether it was safe.

## How the study was done

A prospective phase II trial with no comparison group in 25 adults with metastatic kidney cancer. Each person got IM862 intranasally (through the nose) at the trial's dose of 20 mg three times a day, in 8-week cycles.

<!--promo-->

PepVault for iPhone

## Taking thymogen? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What they found

None of the 25 patients had a significant objective response, meaning tumors did not shrink by a meaningful amount. 8 patients had stable disease (no growth) and 17 got worse while on treatment, with a median time to progression of 1.9 months and median survival of 7.9 months. Among 24 patients checked for side effects, none had grade 2 or 3 side effects tied to the drug. Blood levels of VEGF, a marker linked to blood vessel growth, fell significantly after 4 and 8 weeks.

## What it doesn’t show

This was a small trial with no control arm, so it can't separate drug effects from the natural course of the disease. It tested only one dose and schedule, given alone, in one type of cancer.

## The paper

Deplanque et al. Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma. Br J Cancer. 2004.

- [PubMed (PMID 15354209)](https://pubmed.ncbi.nlm.nih.gov/15354209/)
- [The paper (DOI 10.1038/sj.bjc.6602126)](https://doi.org/10.1038/sj.bjc.6602126)

## The compound

- [Thymogen: how it works, half-life, studied range and evidence](https://pepvault.app/peptides/thymogen)

## With this study

### Thymogen

- [Thymogen: the full reference](https://pepvault.app/peptides/thymogen)

### Studies

- [Thymogen (IM862): 36% major responses in AIDS-related Kaposi's sarcoma](https://pepvault.app/research/thymogen-tulpule-2000)
- [All 2 studies](https://pepvault.app/research#thymogen)

### Compared with

- [Thymalin vs Thymogen](https://pepvault.app/peptides/compare/thymalin-vs-thymogen)

### Tools

- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Intranasal](https://pepvault.app/glossary/intranasal)
- [Cycle](https://pepvault.app/glossary/cycle)

## More studies on Thymogen

- [Thymogen (IM862): 36% major responses in AIDS-related Kaposi's sarcoma](https://pepvault.app/research/thymogen-tulpule-2000) Randomized trial · people · 2000
- [Every study on Thymogen](https://pepvault.app/research#thymogen)

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed November 2026. Spot an error? [feedback@pepvault.app](mailto:feedback@pepvault.app). [How we research](https://pepvault.app/guides/how-we-research). This page reports one study; it is not medical advice.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking thymogen? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking thymogen? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this study

### Thymogen

- [Thymogen: the full reference](https://pepvault.app/peptides/thymogen)

### Studies

- [Thymogen (IM862): 36% major responses in AIDS-related Kaposi's sarcoma](https://pepvault.app/research/thymogen-tulpule-2000)
- [All 2 studies](https://pepvault.app/research#thymogen)

### Compared with

- [Thymalin vs Thymogen](https://pepvault.app/peptides/compare/thymalin-vs-thymogen)

### Tools

- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Intranasal](https://pepvault.app/glossary/intranasal)
- [Cycle](https://pepvault.app/glossary/cycle)

<!--promo-->

PepVault for iPhone

## Taking thymogen? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## Research

- [All studies](https://pepvault.app/research)
- [Every study on Thymogen](https://pepvault.app/research#thymogen)

## The library

- [Thymogen](https://pepvault.app/peptides/thymogen)
- [The peptide reference library](https://pepvault.app/peptides)

## How we work

- [How we research](https://pepvault.app/guides/how-we-research)
- [How we check the library](https://pepvault.app/about#library)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
